Ashwani Rajput, a cancer surgeon and researcher with an interest in health care disparities, was appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, D.C., region.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
